Per Person,  Acarix CEO presented the CADScor® System at the Emerging Medtech Summit in California, USA, last month. Acarix gained interest from several parties interested to support our journey towards presence in the US market.   


Last week we had the opportunity to present and represent Acarix and our CADScor(R)system at the Emerging Medtech Summit in the US. The meeting was attended by more than 400 engaged participants coming from both from the industry and market access communities as well as from the investor side. One highlight was the opportunity to present the CADScor(R) and Acarix for all attendees, presenting the unique innovation and improvement it offers. In addition we gained traction and interest from several stakeholders being able to support and help develop the early work started on our journey towards the US market.   


About Acarix
Acarix is a Swedish medical device company that innovates solutions for rapid AI-based rule out of Coronary Artery Disease (CAD). The CE approved and FDA DeNovo cleared Acarix CADScor®System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive and costly diagnostic procedures. The CADScor system calculates a patient-specific CAD-score non-invasively in less than10 minutes and can help rule out more than one third of patients with at least 96% certainty of not being sick (in a population with approx. 10% CAD prevalence). Acarix is listed on the Nasdaq First North Premier Growth Market (ticker: ACARIX). Redeye AB (+46 (0)8 121 576 90, is Certified Advisor of Acarix.

For more information, please visit